Bicycle Therapeutics (NASDAQ:BCYC) Receives “Buy” Rating from JMP Securities

JMP Securities reissued their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYCGet Rating) in a research note published on Thursday morning. They currently have a $70.00 price objective on the stock.

BCYC has been the subject of a number of other research reports. Piper Sandler reduced their price target on Bicycle Therapeutics from $76.00 to $37.00 and set an overweight rating for the company in a research report on Monday, May 23rd. SVB Leerink boosted their price target on Bicycle Therapeutics from $48.00 to $50.00 and gave the stock an outperform rating in a research report on Monday, August 22nd. HC Wainwright reduced their price target on Bicycle Therapeutics from $65.00 to $57.00 and set a buy rating for the company in a research report on Friday, August 5th. Barclays began coverage on Bicycle Therapeutics in a research note on Thursday, July 28th. They issued an overweight rating and a $30.00 price objective on the stock. Finally, Canaccord Genuity Group reissued a buy rating and issued a $60.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, July 6th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $57.08.

Bicycle Therapeutics Trading Down 0.9 %

NASDAQ:BCYC opened at $25.10 on Thursday. Bicycle Therapeutics has a 12-month low of $12.08 and a 12-month high of $62.08. The firm has a market capitalization of $744.87 million, a P/E ratio of -8.23 and a beta of 0.71. The company has a debt-to-equity ratio of 0.10, a current ratio of 9.88 and a quick ratio of 9.88. The business has a 50 day simple moving average of $23.65 and a 200 day simple moving average of $26.47.

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Bicycle Therapeutics had a negative return on equity of 30.07% and a negative net margin of 533.03%. Equities research analysts predict that Bicycle Therapeutics will post -3.8 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale raised its position in Bicycle Therapeutics by 10.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the company’s stock valued at $562,000 after buying an additional 1,200 shares during the period. Prospera Financial Services Inc purchased a new position in Bicycle Therapeutics in the first quarter valued at about $88,000. State Street Corp grew its stake in Bicycle Therapeutics by 27.9% in the first quarter. State Street Corp now owns 10,687 shares of the company’s stock valued at $469,000 after purchasing an additional 2,333 shares in the last quarter. Quantbot Technologies LP purchased a new position in Bicycle Therapeutics in the second quarter valued at about $60,000. Finally, Claro Advisors LLC purchased a new position in Bicycle Therapeutics in the fourth quarter valued at about $221,000. 76.45% of the stock is owned by institutional investors and hedge funds.

About Bicycle Therapeutics

(Get Rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Recommended Stories

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.